NCR300

Phase 1Small molecule

NNuwacell Biotechnologies Co., Ltd.

NCR300 is one of 85 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaNot yet recruiting

Myelodysplastic SyndromesNot yet recruiting

Acute Myeloid LeukemiaPhase 1

Not yet recruiting

Myelodysplastic SyndromesPhase 1

Not yet recruiting

Competition

Competitive Landscape

235 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

60 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Fludara

Sanofi

Phase 3

18 5

Vanflyta

Daiichi Sankyo

Phase 3

16 6

Vepesid

AAvyxa

Phase 3

52 7

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

42 8

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 9

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

32 10

Neupogen

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1Not yet recruiting

Acute Myeloid Leukemia

NCT06441084

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

Not yet recruiting·NNuwacell Biotechnologies Co., Ltd.·Phase 1·NCT06441084·15 enrolled

Myelodysplastic Syndromes1 trial

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes

Not yet recruiting·NNuwacell Biotechnologies Co., Ltd.·Phase 1·NCT05371730·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NCR300. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NCR300 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NCR300. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nuwacell Biotechnologies Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNuwacell Biotechnologies Co., Ltd.

NCR300

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Acute Myeloid Leukemia1 trial

Myelodysplastic Syndromes1 trial

References

Drug Info

Quick Facts

Related News